![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Lawmakers Call for Azar’s Intervention on HCV Drug Prices
Lawmakers Call for Azar’s Intervention on HCV Drug Prices
![](https://www.fdanews.com/ext/resources/test/Drug-Images3/CuttingMoney.gif?t=1433878515&width=430)
February 26, 2018
Citing a public health emergency, a group of congressional Democrats called on HHS Secretary Alex Azar to use existing legislative authority to lower the price of hepatitis C virus treatments.
The Feb. 15 letter states that Azar may use existing authority under 28 U.S.C. 1498, which authorizes federal agencies to use patented inventions “for a reasonable and entire compensation” when used in the interest of the government.
“With 20,000 Americans currently dying from hepatitis C every year, it is evident that the epidemic is well beyond any potential threshold for declaring a public health emergency,” the letter said.
Many hepatitis C deaths directly resulted from patients being unable to access treatments due to high prices such as Gilead’s Harvoni (ledipasvir and sofosbuvir) and AbbVie’s Mavyret (glecaprevir and pibrentasvir), the letter stated.
Upcoming Events
-
21Oct